Effective treatment of mogamulizumab-induced head and neck dermatitis with fluconazole in a patient with peripheral T-Cell lymphoma

[1]  C. Querfeld,et al.  Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T‐cell lymphoma: a retrospective single‐centre case series * , 2021, The British journal of dermatology.

[2]  F. Craig,et al.  Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome , 2021, JAAD case reports.

[3]  K. Carson,et al.  Mogamulizumab-Associated Cutaneous Granulomatous Drug Eruption Mimicking Mycosis Fungoides but Possibly Indicating Durable Clinical Response. , 2019, JAMA dermatology.

[4]  J. Greenbaum,et al.  Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression , 2018, Cell.

[5]  C. Elmets,et al.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.

[6]  Simon C Watkins,et al.  Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome , 2018, Cancer Immunology, Immunotherapy.

[7]  F. Haesebrouck,et al.  The Yin and Yang of regulatory T cells in infectious diseases and avenues to target them , 2017, Cellular microbiology.

[8]  A. Abbas,et al.  Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing , 2016, The Journal of Immunology.

[9]  A. Mogi,et al.  Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab , 2015, International Journal of Hematology.

[10]  B. Kaffenberger,et al.  A retrospective descriptive study of oral azole antifungal agents in patients with patch test-negative head and neck predominant atopic dermatitis. , 2014, Journal of the American Academy of Dermatology.

[11]  M. Taniwaki,et al.  Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Karbach,et al.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.

[13]  T. Chatila,et al.  Skin Inflammation Arising from Cutaneous Regulatory T Cell Deficiency Leads to Impaired Viral Immune Responses , 2010, The Journal of Immunology.

[14]  K. Ohshima,et al.  Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma , 2010, International journal of hematology.